{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:39:57Z","timestamp":1777667997139,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess the prevalence, characteristics, and healthcare resource utilization (HCRU) of patients prescribed certain benzodiazepines for seizure\u2010emergency management in the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study using Clinical Practice Research Datalink (CPRD\u2010Aurum) and Hospital Episode Statistics (HES) data that included patients with \u22651 recorded seizure\u2010emergency medication prescription between 2016 and 2020. Patient characteristics were described for the whole sample. Inpatient, outpatient, and Accident and Emergency (A&amp;E) encounters during 2019 were described. The 2019 prevalence of seizure\u2010emergency medication prescription among patients with epilepsy was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2019, 6.7% (9336\/139667) of CPRD\u2010Aurum patients with epilepsy were prescribed seizure\u2010emergency medication. Between 2016 and 2020, 26\u2009534 patients with seizure\u2010emergency medication were identified (mean\/median age: 41.5\/41.0\u2009years [71.8% were adults]; 50.3% male). In this sample, the most prescribed seizure\u2010emergency medication was buccal midazolam (60.6% of patients). Rectal diazepam was prescribed for 19.0%; oral benzodiazepines for 20.3%. Of the oral benzodiazepines prescribed for seizure\u2010emergency management, oral diazepam was most common (97.5%). Buccal midazolam was prescribed both to children and adults (44.2%\/55.8%); rectal diazepam and oral benzodiazepines mainly to adults (93.3%\/99.5%). Among 11\u2009594 patients with HES linkage in 2019, 25.1% experienced \u22651 epilepsy\u2010specific inpatient hospitalization (median hospitalization days in patients with \u22651 hospitalization\u2009=\u20092.9 [IQR 12.0]); 35.7% had \u22651 neurology\u2010specific outpatient visit (median visits in patients with \u22651 visit\u2009=\u20092.6 [3.4]); 8.7% had \u22651 epilepsy\u2010related emergency attendance (median attendances in patients with \u22651 attendance\u2009=\u20093.0 [4.0]); 7.8% arrived in A&amp;E by ambulance due to epilepsy (median arrivals in patients with \u22651 arrival\u2009=\u20092.2 [3.4]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>In 2019, 6.7% of patients with epilepsy were prescribed seizure\u2010emergency medication. Nevertheless, patients continue to encounter challenges to manage seizure\u2010related emergencies, as shown by high HCRU, suggesting that it may be time for a new treatment paradigm. The recently proposed concept of Rapid and Early Seizure Termination (REST) warrants further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>In people with epilepsy, some seizures last too long and will not stop on their own, or may happen one after another, becoming emergencies that need medical attention; seizure\u2010emergency medications are given to stop the seizure and prevent other medical problems. We looked at the share of people with epilepsy who had a seizure\u2010emergency medication prescription in a UK database, and this group's use of health services. In 2019, 7% of people with epilepsy were prescribed a seizure\u2010emergency medication. Use of health services was high in this group, highlighting the need for better treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epi4.70035","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:41:28Z","timestamp":1747204888000},"page":"1023-1033","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medications used for seizure\u2010emergency management in the\n                    <scp>UK<\/scp>\n                    community: A clinical practice research datalink retrospective database study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0677-015X","authenticated-orcid":false,"given":"Yuanjun","family":"Ma","sequence":"first","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Hastie","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-0465","authenticated-orcid":false,"given":"Ana Paula","family":"Bartmann","sequence":"additional","affiliation":[{"name":"UCB  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Laloyaux","sequence":"additional","affiliation":[{"name":"UCB  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-7981","authenticated-orcid":false,"given":"Simon","family":"Borghs","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02000.x"},{"key":"e_1_2_11_3_1","unstructured":"PenovichP.Acute repetitive seizures (ARS) or cluster seizures. [accessed April 15 2024]. Available from:https:\/\/www.epilepsyfoundationmn.org\/2020\/01\/14\/acute\u2010repetitive\u2010seizures\u2010ars\u2010or\u2010cluster\u2010seizures\/"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2020.100409"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb00073.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14515"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1661-x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2105207"},{"issue":"1","key":"e_1_2_11_9_1","first-page":"S34","article-title":"Rescue therapies for seizure clusters: pharmacology and target of treatments","volume":"63","author":"Gidal B","year":"2022","journal-title":"Epilepsia"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.09.035"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.1689"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.20243"},{"key":"e_1_2_11_14_1","unstructured":"National Institute for Health and Care Excellence.Epilepsies in children young people and adults. [accessed April 15 2024]. Available from:https:\/\/www.nice.org.uk\/guidance\/ng217\/chapter\/7\u2010Treating\u2010status\u2010epilepticus\u2010repeated\u2010or\u2010cluster\u2010seizures\u2010and\u2010prolonged\u2010seizures"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.05.013"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00515-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000140"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17155"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3310\/RSVK2062"},{"key":"e_1_2_11_20_1","unstructured":"European Medicines Agency.Buccolam\u00ae (buccal midazolam). European Union Summary of Product Characteristics. [accessed April 15 2024]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/buccolam\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_21_1","unstructured":"National Institute for Health and Care Excellence.Epilepsies: diagnosis and management. [accessed April 26 2023]. Available from:https:\/\/www.nice.org.uk\/guidance\/cg137"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0544-2"},{"key":"e_1_2_11_23_1","unstructured":"European Medicines Agency.Summary of opinion (initial authorisation): Buccolam. [accessed February 5 2025]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/chmp\u2010summary\u2010positive\u2010opinion\u2010buccolam_en.pdf"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525\u20105050(02)00559\u20100"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00940-2"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108242"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.10.007"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:44:15Z","timestamp":1767109455000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/epi4.70035"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70035","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}